Pre-Submission Communication Issues May Hurt Regeneron’s Arcalyst In Gout
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA warned in pre-submission meetings that the company’s safety database may not be adequate and those questions remain as the application goes to the Arthritis Advisory Committee.